No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SHTDY SINOPHARM GROUP CO
- 13.319
- -0.145-1.07%
15min DelayTrading Apr 23 11:15 ET
8.31BMarket Cap6.65P/E (TTM)
13.480High13.300Low720Volume13.480Open13.464Pre Close9.61KTurnover0.00%Turnover Ratio6.65P/E (Static)624.13MShares17.25952wk High0.79P/B8.31BFloat Cap11.35552wk Low0.59Dividend TTM624.13MShs Float24.356Historical High4.41%Div YieldTTM1.34%Amplitude7.620Historical Low13.341Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
Sinopharm Holdings (01099.HK) plans to hold a board meeting on April 26 to approve quarterly results
Gelonghui, April 16, 丨 Sinopharm Holdings (01099.HK) announced that the board of directors will hold a board meeting on April 26, 2024 (Friday) to consider and approve (including) the unaudited quarterly results of the company and its subsidiaries for the three months ended March 31, 2024.
國藥控股：董事會會議通告
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might
Sinopharm Holdings received 997,600 additional shares from FMR LLC at a price of approximately HK$20.49 per share
According to the latest data from the Hong Kong Stock Exchange, on April 2, FMR LLC increased its holdings of Sinopharm Holdings (01099) by 997,600 shares, at a price of HK$20.4938 per share, for a total amount of about HK$204.44,600. After the increase in holdings, the latest number of shares held was about 162 million shares, and the latest shareholding ratio was 12.04%.
Sinopharm Holdings (01099.HK) gains 997,600 shares from FMR LLC
Gelonghui, April 9 | According to the latest equity disclosure data on the Stock Exchange, on April 2, 2024, Sinopharm Holdings (01099.HK) received FMR LLC an increase of 997,600 shares at an average price of HK$20.4938 per share on the market, involving approximately HK$20.445 million. After the increase in holdings, FMR LLC's latest shareholding was 161,576,874 shares, and the shareholding ratio increased from 11.97% to 12.04%.
Comments
Analysts have downgraded their earnings per share estimates for Sinopharm Group, indicating a decline in sentiment. They also suggest that Sinopharm may underperform compared to the wider industry, but the consensus price target remains steady.
Earnings Update: Sinopharm Group Co. Ltd. (HKG:1099) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts 2
Sinopharm Group's declining ROCE trend is concerning. Increased capital investment without matching sales suggests long-term plays. High current liabilities to total assets ratio introduces risk. These trends indicate Sinopharm may not be a multi-bagger.
1
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
$Hang Seng Index(800000.HK$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
Pharmaceuticals were sold off. $REMEGEN(09995.HK$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH(01873.HK$ ...
1
Sinopharm Group's low P/E ratio is due to investors' limited growth expectations, leading to a reduced stock price. The poor earnings outlook from analysts also contributes to its low P/E. These conditions may continue to hinder the share price.
Sinopharm Group is currently undervalued and it might be a good time to accumulate more holdings in the stock. The positive outlook on the horizon of the company's future seems not to be fully factored into the current share price.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg